Ibrutinib‐associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non‐Hodgkin lymphoma: An observational study
Rosa Ruchlemer(Shaare Zedek Medical Center), Tamar Lachish(Shaare Zedek Medical Center), Koh Okamoto(Rush University Medical Center), Yair Herishanu(Tel Aviv University), Jennifer R. Brown(Dana-Farber Cancer Institute), Talha Munir(Leeds Teaching Hospitals NHS Trust), Naama Bogot(Shaare Zedek Medical Center), Marcel Nijland(University Medical Center Groningen), Rogier Mous(University Medical Center Utrecht), Tamar Tadmor(Bnai Zion Medical Center), Carole Soussain(Institut Curie), Benjamin J. Arthurs(VA Portland Health Care System), Ronen Ben‐Ami(Tel Aviv University), Maya Korem(Hadassah Medical Center), Regev Cohen(Laniado Hospital), Ohad Benjamini(Sheba Medical Center), Julia A. Messina(Duke University), Maskit Bar‐Meir(Hebrew University of Jerusalem), Noélie Barzic(Hôpital Lyon Sud), Arnon P. Kater(Amsterdam University Medical Centers), Marion Malphettes(Hôpital Saint-Louis), Preetesh Jain(The University of Texas MD Anderson Cancer Center), Fransien de Boer(Ikazia Ziekenhuis), Stephen P. Mulligan(Royal North Shore Hospital), Barbara Eichhorst(University of Cologne), Jacob M. Rowe(City Of Hope National Medical Center), Brian T. Hill(Cleveland Clinic), Bat‐Sheva Gottesman(Meir Medical Center), Sanne H. Tonino(Amsterdam UMC Location University of Amsterdam)
Cited by 80
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium
|The Lancet Infectious Diseases|2019|1.7k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k